... Food and Drug Administration Highlights of Prescribing Information: Elrexfio — Pfizer Highlights of Prescribing Information: Lynozyfic — Regeneron Pharmaceuticals Highlights of Prescribing Information: Talvey — Janssen Pharmaceutical Companies What Do Clinical Trial Results Mean? ...
... Healthcare Database (SNDS) — Annals of Hematology The Value of Survival Gains From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey ...
What Is the Life Expectancy With Relapsed/Refractory Myeloma?
... Healthcare Database (SNDS) — Annals of Hematology The Value of Survival Gains From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey ...
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
Can Multiple Myeloma Be Cured? Advances in Research and Survival
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
... Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. Selinexor (Xpovio) is a nuclear export inhibitor that disrupts how cancer cells function and grow. New treatments are being developed through laboratory work and clinical trials. ...
Relapsed vs. Refractory: What It Means in Multiple Myeloma
... Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. Selinexor (Xpovio) is a nuclear export inhibitor that disrupts how cancer cells function and grow. New treatments are being developed through laboratory work and clinical trials. ...
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
Myeloma Treatment Journey: From First Line to Fourth Line
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
... individuals with relapsed or refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey ...
Multiple Myeloma – An Overview
... individuals with relapsed or refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey ...
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
8 Refractory Myeloma Therapies: Know Your Treatment Options
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
... Talquetamab (Talvey) is a bispecific T-cell engager approved in 2023 for people with RRMM who have tried four lines of therapy. In 2025, the FDA approved linvoseltamab-gcpt (Lynozyfic) for adults with RRMM who have received four or more prior lines of treatment.BiTEs work by targeting BCMA and the CD3 protein found in T cells. ...
Myeloma Relapse Rates and 9 Treatment Options for Relapses
... Talquetamab (Talvey) is a bispecific T-cell engager approved in 2023 for people with RRMM who have tried four lines of therapy. In 2025, the FDA approved linvoseltamab-gcpt (Lynozyfic) for adults with RRMM who have received four or more prior lines of treatment.BiTEs work by targeting BCMA and the CD3 protein found in T cells. ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Myeloma Treatments: Risks and Benefits
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
12 Myeloma Treatment Options
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
Join
